StockData
Pure Bioscience, Inc. logo

Pure Bioscience, Inc. (PURE) stock

PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
Financials through Q4 FY2026, quarter ended Jul 31, 2026Last filing: 10-K on Oct 29, 2026Score 1/30
$0.07−0.01 (-12.10%)

Close on Oct 19, 2026Market cap $8.67MP/E –Yield –

Pure Bioscience operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Pure Bioscience's operating cash flow for the twelve months ending Jul 31, 2026 was -$1.74M. For fiscal 2026 it was -$1.74M. The highest annual figure on record is $669.00K in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Jul 31, 2026-$1.74M–
FY2025Jul 31, 2025-$2.02M–
FY2024Jul 31, 2024-$2.53M–
FY2023Jul 31, 2023-$3.28M–
FY2022Jul 31, 2022-$2.42M–
FY2021Jul 31, 2021-$1.17M-274.4%
FY2020Jul 31, 2020$669.00K–
FY2019Jul 31, 2019-$2.99M–
FY2018Jul 31, 2018-$3.89M–
FY2017Jul 31, 2017-$4.56M–
FY2016Jul 31, 2016-$4.99M–
FY2015Jul 31, 2015-$6.06M–
FY2014Jul 31, 2014-$6.33M–
FY2013Jul 31, 2013-$3.90M–
FY2012Jul 31, 2012-$5.59M–
FY2011Jul 31, 2011-$6.12M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jul 31, 2026-$414.00K–
Q3 FY2026CQ1 2026Apr 30, 2026-$468.00K–
Q2 FY2026CQ4 2025Jan 31, 2026-$606.00K–
Q1 FY2026CQ3 2025Oct 31, 2025-$250.00K–
Q4 FY2025CQ2 2025Jul 31, 2025-$456.00K–
Q3 FY2025CQ1 2025Apr 30, 2025-$512.00K–
Q2 FY2025CQ4 2024Jan 31, 2025-$544.00K–
Q1 FY2025CQ3 2024Oct 31, 2024-$503.00K–
Q4 FY2024CQ2 2024Jul 31, 2024-$593.00K–
Q3 FY2024CQ1 2024Apr 30, 2024-$615.00K–
Q2 FY2024CQ4 2023Jan 31, 2024-$883.00K–
Q1 FY2024CQ3 2023Oct 31, 2023-$440.00K–
Q4 FY2023CQ2 2023Jul 31, 2023-$744.00K–
Q3 FY2023CQ1 2023Apr 30, 2023-$665.00K–
Q2 FY2023CQ4 2022Jan 31, 2023-$967.00K–
Q1 FY2023CQ3 2022Oct 31, 2022-$902.00K–
Q4 FY2022CQ2 2022Jul 31, 2022-$603.00K–
Q3 FY2022CQ1 2022Apr 30, 2022-$609.00K–
Q2 FY2022CQ4 2021Jan 31, 2022-$630.00K–
Q1 FY2022CQ3 2021Oct 31, 2021-$576.00K–
Q4 FY2021CQ2 2021Jul 31, 2021-$412.00K-122.5%
Q3 FY2021CQ1 2021Apr 30, 2021-$347.00K–
Q2 FY2021CQ4 2020Jan 31, 2021-$209.00K–
Q1 FY2021CQ3 2020Oct 31, 2020-$199.00K–
Q4 FY2020CQ2 2020Jul 31, 2020$1.83M–
Q3 FY2020CQ1 2020Apr 30, 2020-$224.00K–
Q2 FY2020CQ4 2019Jan 31, 2020-$614.00K–
Q1 FY2020CQ3 2019Oct 31, 2019-$324.00K–
Q4 FY2019CQ2 2019Jul 31, 2019-$656.00K–
Q3 FY2019CQ1 2019Apr 30, 2019-$833.00K–
Q2 FY2019CQ4 2018Jan 31, 2019-$441.00K–
Q1 FY2019CQ3 2018Oct 31, 2018-$1.06M–
Q4 FY2018CQ2 2018Jul 31, 2018-$664.00K–
Q3 FY2018CQ1 2018Apr 30, 2018-$1.10M–
Q2 FY2018CQ4 2017Jan 31, 2018-$1.09M–
Q1 FY2018CQ3 2017Oct 31, 2017-$1.03M–
Q4 FY2017CQ2 2017Jul 31, 2017-$1.17M–
Q3 FY2017CQ1 2017Apr 30, 2017-$1.17M–
Q2 FY2017CQ4 2016Jan 31, 2017-$1.18M–
Q1 FY2017CQ3 2016Oct 31, 2016-$1.05M–

More Pure Bioscience figures

See a number that looks wrong?